This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2004 Feb 14;328(7436):358-9.

doi: 10.1136/bmj.328.7436.358.

Thalassaemia major: the murky story of deferiprone

Julian Savulescu

PMID: 14962851
PMCID: PMC341373
DOI: 10.1136/bmj.328.7436.358

Editorial

Thalassaemia major: the murky story of deferiprone

Julian Savulescu. BMJ. 2004.

. 2004 Feb 14;328(7436):358-9.

doi: 10.1136/bmj.328.7436.358.

Author

Julian Savulescu

PMID: 14962851
PMCID: PMC341373
DOI: 10.1136/bmj.328.7436.358

No abstract available

PubMed Disclaimer

Similar articles

Adherence to desferrioxamine and deferiprone and the impact of deferiprone co-prescription in thalassaemia major patients. Does the addition of deferiprone improve adherence?
Kidson-Gerber G, Lindeman R. Kidson-Gerber G, et al. Br J Haematol. 2008 Aug;142(4):679-80. doi: 10.1111/j.1365-2141.2008.07234.x. Epub 2008 Jun 5. Br J Haematol. 2008. PMID: 18537970 No abstract available.
Iron chelating in thalassaemia with left ventricular dysfunction.
Cagirci G, Tufekcioglu O, Yetim M. Cagirci G, et al. Heart. 2006 Oct;92(10):1440. doi: 10.1136/hrt.2006.088377. Heart. 2006. PMID: 16973798 Free PMC article. No abstract available.
Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
Brittenham GM, Nathan DG, Olivieri NF, Pippard MJ, Weatherall DJ. Brittenham GM, et al. Lancet. 2003 Jan 11;361(9352):183; author reply 183-4. doi: 10.1016/s0140-6736(03)12223-4. Lancet. 2003. PMID: 12531619 No abstract available.
Compliance with iron chelation therapy in beta thalassaemia.
Vidler V. Vidler V. Paediatr Nurs. 1998 Oct;10(8):17-8, 20. Paediatr Nurs. 1998. PMID: 10095669 Review. No abstract available.
Advances in experimental treatment of beta-thalassaemia.
Rodgers GP, Saunthararajah Y. Rodgers GP, et al. Expert Opin Investig Drugs. 2001 May;10(5):925-34. doi: 10.1517/13543784.10.5.925. Expert Opin Investig Drugs. 2001. PMID: 11322866 Review.

See all similar articles

Cited by

World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.
Kontoghiorghe CN, Andreou N, Constantinou K, Kontoghiorghes GJ. Kontoghiorghe CN, et al. World J Methodol. 2014 Sep 26;4(3):163-88. doi: 10.5662/wjm.v4.i3.163. eCollection 2014 Sep 26. World J Methodol. 2014. PMID: 25332915 Free PMC article. Review.
The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia.
Kontoghiorghes GJ, Kleanthous M, Kontoghiorghe CN. Kontoghiorghes GJ, et al. Mediterr J Hematol Infect Dis. 2020 Jan 1;12(1):e2020011. doi: 10.4084/MJHID.2020.011. eCollection 2020. Mediterr J Hematol Infect Dis. 2020. PMID: 31934321 Free PMC article. Review.
Intermicrobial interaction: Aspergillus fumigatus siderophores protect against competition by Pseudomonas aeruginosa.
Sass G, Ansari SR, Dietl AM, Déziel E, Haas H, Stevens DA. Sass G, et al. PLoS One. 2019 May 8;14(5):e0216085. doi: 10.1371/journal.pone.0216085. eCollection 2019. PLoS One. 2019. PMID: 31067259 Free PMC article.
Take Two Iron Chelators and Call Me in the Morning.
Fliesler SJ. Fliesler SJ. Transl Vis Sci Technol. 2012 Oct 25;1(3):2a. doi: 10.1167/tvst.1.3.2a. eCollection 2012. Transl Vis Sci Technol. 2012. PMID: 24049710 Free PMC article. No abstract available.
New developments and controversies in iron metabolism and iron chelation therapy.
Kontoghiorghe CN, Kontoghiorghes GJ. Kontoghiorghe CN, et al. World J Methodol. 2016 Mar 26;6(1):1-19. doi: 10.5662/wjm.v6.i1.1. eCollection 2016 Mar 26. World J Methodol. 2016. PMID: 27019793 Free PMC article.

See all "Cited by" articles

References

1. Piga A, Gagliotti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003;88: 489-96. - PubMed
1. Spurgeon D. Trials sponsored by drug companies: review ordered. BMJ 1998;317: 618. - PubMed
1. The Olivieri symposium. J Med Ethics 2004;30: 1-52. - PMC - PubMed
1. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998:339: 417-23. - PubMed
1. Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R, et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 2002;100: 1566-9. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources